Yahoo Poland Wyszukiwanie w Internecie

Search results

1. www.lumithera.com › category › press-releasesPress Releases and Events - LumiThera

   www.lumithera.com › category › press-releases

   • Zapisane w pamięci cache

   SEATTLE, March 22, 2022 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced positive findings in its LIGHTSITE III, multi-center clinical trial in non-neovascular (dry) Age-Related Macular Degeneration (AMD) subjects treated with ...

2. finance.yahoo.com › news › lumithera-announces-initiation-eurolight-registryLumiThera Announces Initiation of EUROLIGHT Registry Study to...

   finance.yahoo.com › news › lumithera-announces-initiation-eurolight-registry

   • Zapisane w pamięci cache

   16 sty 2024 · SEATTLE, January 16, 2024 -- ( BUSINESS WIRE )--LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the...

3. www.lumithera.com › lumithera-presents-us-lightsite-iii-trial-data-showingLumiThera Presents US LIGHTSITE III Trial Data Showing...

   www.lumithera.com › lumithera-presents-us-lightsite-iii-trial-data-showing

   • Zapisane w pamięci cache

   22 cze 2022 · SEATTLE, June 22, 2022 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced detailed findings in its LIGHTSITE III, multi-center clinical trial in non-neovascular (dry) Age-Related Macular Degeneration (AMD) subjects treated with ...

4. www.businesswire.com › news › homeLumiThera Announces Sustained Vision Improvement for 24 months in...

   www.businesswire.com › news › home

   • Zapisane w pamięci cache

   15 mar 2023 · LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the 24-month data.

5. www.prnewswire.com › news-releases › lumithera-presents-us-lightsite-iii-trialLumiThera Presents US LIGHTSITE III Trial Data Showing...

   www.prnewswire.com › news-releases › lumithera-presents-us-lightsite-iii-trial

   • Zapisane w pamięci cache

   22 cze 2022 · SEATTLE, June 22, 2022 /PRNewswire/ -- LumiThera Inc., a commercial stage medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced...

6. www.lumithera.comHome | LumiThera US

   www.lumithera.com

   • Zapisane w pamięci cache

   LumiThera is a medical device company at the forefront in the development of photobiomodulation (PBM) treatment protocols for patients with dry AMD. Age-related macular degeneration (AMD) is the leading cause of blindness in adults over 65.

7. finance.yahoo.com › news › lumithera-provides-fda-review-valeda-121200468LumiThera Provides Update on FDA Review of Valeda Treatment for...

   finance.yahoo.com › news › lumithera-provides-fda-review-valeda-121200468

   • Zapisane w pamięci cache

   3 sty 2024 · SEATTLE, January 03, 2024 -- ( BUSINESS WIRE )--LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced an update on...